BIOCON PHARMA LTD

Biocon Pharma Ltd. is primarily a factory or manufacturer.

Company Introduction:

Biocon Pharma Ltd. is a leading Indian biopharmaceutical company headquartered in Bangalore, India. It is a fully integrated, innovation-led global biopharmaceutical enterprise committed to reducing the burden of chronic diseases. Biocon specializes in the development, manufacturing, and commercialization of novel biologics, biosimilars, and complex small molecule APIs (Active Pharmaceutical Ingredients). The company's therapeutic focus areas include diabetes, oncology, and immunology. Biocon has a strong emphasis on research and development, operating state-of-the-art manufacturing facilities that adhere to global regulatory standards. Their business model involves discovering, developing, manufacturing, and marketing their own pharmaceutical products globally, rather than just trading products manufactured by others.

Biocon Pharma Ltd. manufactures or sells products primarily in the areas of biopharmaceuticals, biosimilars, and novel therapies.

Its product portfolio includes biosimilar insulins such as recombinant human insulin marketed as Insugen and Wosulin, Insulin Glargine known as Basalog, Insulin Aspart, and Insulin Lispro.

In oncology, Biocon offers biosimilar Trastuzumab marketed as CANMAb and Ogivri, biosimilar Bevacizumab known as Bevac, and biosimilar Pegfilgrastim marketed as Pegfilgrine and Fulphila.

For immunology and autoimmune conditions, products include biosimilar Adalimumab known as Hulio, and the novel biologic Itolizumab marketed as ALZUMAb, which is used for psoriasis and certain inflammatory indications.

The company also provides biosimilar Erythropoietin known as Erypro for nephrology. Other biosimilar offerings include Filgrastim and Etanercept.

Biocon's focus is on therapeutic areas like diabetes, oncology, immunology, and nephrology, providing a comprehensive range of biologics and biosimilars.